DT
David Thomas
Australian Genomic Cancer Medicine Centre t/as Omico, Government of New South Wales, The University of Melbourne, Royal Australasian College of Physicians, UNSW Sydney
Research areas: Biochemistry, Genetics and Molecular Biology · Genetics · Sarcoma Diagnosis and Treatment · Cancer Genomics and Diagnostics · BRCA gene mutations in cancer
0000-0002-2527-5428
Employment
-
Australian Genomic Cancer Medicine Centre t/as Omico Chief Scientist and Strategy Officer2024 - Present
-
Government of New South Wales Director2023 - Present
-
University of New South Wales Director2023 - Present
-
Australian Genomic Cancer Medicine Centre t/as Omico CEO2015 - 2023
-
Garvan Institute of Medical Research Lab Head2014 - 2024
Education
- 1993 - 1995
- 1992 - 1997
- 1982 - 1988
Projects & Funding
-
Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment National Cancer Institute2022 - 2027
-
Genomic Cancer Medicine National Health and Medical Research Council2021 - 2025
-
Synthetic DNA Standards for Clinical Genome Sequencing National Health and Medical Research Council2018 - 2020
-
Immunotherapy in cancer and virus infection National Health and Medical Research Council2018 - 2022
-
An international whole genome study to definitively map heritable risk in sarcomas National Health and Medical Research Council2017 - 2017
-
Diagnosing Chromosomal Translocations in Solid Tumours National Health and Medical Research Council2016 - 2017
-
Mechanistic and Functional Drivers of Neochromosome Evolution National Health and Medical Research Council2016 - 2018
-
Genomic Cancer Medicine National Health and Medical Research Council2016 - 2020
-
Targeting the PD-1 pathway in osteosarcoma National Health and Medical Research Council2015 - 2018
-
Stress-induced genomic instability as a driver of adaptive responses in human cancer cells National Health and Medical Research Council2015 - 2017
-
Towards individualized therapy for orphan cancer Southern and Eastern Norway Regional Health Authority2014 - 2018
-
Translational immunobiology of osteosarcoma National Health and Medical Research Council2013 - 2015
-
Identification of novel familial patterns and genotypes associated with inherited risk in adult-onset sarcoma: the International Sarcoma Kindred Study National Health and Medical Research Council2011 - 2013
-
Translational Research in Sarcomas National Health and Medical Research Council2011 - 2015
-
Molecular pathways mediating the anti-tumour activity of WIF1 National Health and Medical Research Council2011 - 2013
-
A single nucleotide resolution map of a cancer associated neochromosome National Health and Medical Research Council2011 - 2013
-
In vivo modelling of WIF1 in bone development and tumourigenesis National Health and Medical Research Council2008 - 2010
-
Identification and characterisation of amplified oncogenes in liposarcoma National Health and Medical Research Council2008 - 2010
-
Mechanisms of uptake of 18F-FDG in an in vivo model of c-kit induced neoplasia National Health and Medical Research Council2006 - 2008
-
Molecular profiling of sarcomas to enable clinical prediction and elucidate molecular pathogenesis National Health and Medical Research Council2005 - 2007
-
Molecular Pathogenesis of Sarcoma National Health and Medical Research Council2003 - 2007
Publications (389)
- A conserved thermodynamic signature links transcriptome organization to growth state Save
- The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology Save
- Considerations in Genomic Therapy Matching-Reply. Save
- Population prevalence of high-risk pharmacogenetic configurations in a healthy older Australian reference cohort. Save
- From exclusion to engagement and enrolment: single institutional experience of recruiting Aboriginal and Torres Strait Islander peoples for a genomic sequencing study Save
- Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program Save
- A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma. Save
- BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy. Save
- Bypassing the evidence pathway: World-first tumour-agnostic reimbursement for dual immunotherapy. Save
- Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma. Save
- Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results Save
- Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial. Save
- Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature. Save
- Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation. Save
- A catalogue of early diverged contemporary human genome variation reveals distinct Khoe-San populations Save
- Genomic Therapy Matching in Rare and Refractory Cancers Save
- Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers: A Nonrandomized Clinical Trial Save
- TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors Save
- The Utility of Molecular Tumor Profiling for Patients With Advanced or Rare Cancer in a Regional Australian Setting Save
- SMARCAL1 is a new osteosarcoma predisposition gene. Save